AAV1AAV12

AAV1AAV12 refers to two natural serotypes of adeno-associated virus, AAV1 and AAV12, which are frequently used as vectors for gene delivery in research and, in some cases, clinical settings. AAVs are small, non-enveloped, single-stranded DNA viruses in the Parvoviridae family. In vector form, their genomes are engineered to carry a therapeutic transgene within a packaging capacity of about 4.7 kilobases and are designed to persist as episomes in transduced cells rather than integrate into the host genome.

Capsid and tropism play a central role in differentiating AAV1 and AAV12. The capsid proteins determine cell entry and interaction with cellular receptors, leading to distinct tissue tropisms and transduction efficiencies. AAV1 has been widely used for robust transduction in skeletal muscle and has utility in muscle-directed gene delivery. AAV12 is less commonly applied but has been studied for its activity in certain tissues in animal models, with a serological profile and receptor usage that can differ from AAV1. These differences influence choices for targeting specific tissues and for navigating pre-existing immunity.

Immunogenicity is a key consideration for both serotypes. Pre-existing neutralizing antibodies against AAVs vary across serotypes and populations, and cross-reactivity between serotypes is not always complete. This affects vector performance and the design of clinical strategies, such as patient screening and immunomodulatory approaches.

Applications and considerations: Researchers select serotypes based on target tissue, delivery route, and immune background. AAV1 and AAV12 have been used in preclinical studies; in broader clinical practice, other serotypes (notably AAV9) are often favored for systemic or central nervous system targets. Production remains non-integrating, with standard plasmid-based or other production systems used to generate vectors for research and therapeutic testing.

---